Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BREVIBLOC IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BREVIBLOC IN PLASTIC CONTAINER.
BETAPACE vs BREVIBLOC IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Esmolol is a cardioselective beta-1 adrenergic receptor antagonist with minimal intrinsic sympathomimetic activity and membrane-stabilizing properties. At therapeutic doses, it blocks beta-1 receptors in the myocardium, decreasing heart rate, myocardial contractility, and AV conduction velocity, leading to reduced cardiac output and myocardial oxygen demand.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Initial loading dose: 500 mcg/kg IV over 1 minute, followed by continuous IV infusion of 50 mcg/kg/min for 4 minutes; if inadequate response, repeat loading dose and increase infusion by 50 mcg/kg/min increments up to 200 mcg/kg/min. Maintenance: 25-200 mcg/kg/min continuous IV infusion.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life is approximately 9 minutes (range 4–15 minutes) for the parent drug, leading to rapid offset of effect. The half-life of the metabolite ASL-8123 is about 3.7 hours.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Elimination primarily via red blood cell esterases; renal excretion of unchanged drug is less than 1% of dose. Metabolite ASL-8123 is inactive and renally excreted.
Category C
Category C
Beta-Blocker
Beta-Blocker